
Sarepta Updates UK Dosing in ENVISION Study of ELEVIDYS
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS, the only approved gene therapy for patients

Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS, the only approved gene therapy for patients

The global neuromuscular disease therapeutics market size is estimated to grow by USD 13.73 billion from 2025-2029, according to Technavio. The market is estimated to